Literature DB >> 6223106

Thrombin activity of fibrin thrombi and soluble plasmic derivatives.

C W Francis, R E Markham, G H Barlow, T M Florack, D M Dobrzynski, V J Marder.   

Abstract

Fibrin was prepared from purified fibrinogen, plasma, and pathologic arterial thrombi and assayed for thrombin activity. Activity was detected on fibrin from each of these sources when assayed by three techniques: the rate of release of FPA from fibrinogen, a clotting time assay, and the rate of hydrolysis of the chromogenic substrate S-2238. Of the labeled thrombin initially associated with fibrin during clot formation in vitro, all but 10% to 15% could be removed easily by manual compression or by incubation in buffer. Radiolabeled thrombin that remained bound to clots of purified fibrinogen retained full functional activity, whereas that bound to plasma clots expressed only 4% of expected activity. Plasmic lysis of fibrin from clots of purified fibrinogen released bound thrombin quantitatively into solution in active form. The solubilized thrombin retained association with specific macromolecular fibrin derivatives as demonstrated by sedimentation analysis, electrophoretic co-migration, and partitioning in agarose gel. Plasmic lysates of fibrin prepared in vitro from plasma or pathologic arterial clots also expressed thrombin activity, in an amount similar to the fibrin from which they were prepared. Our studies demonstrate the presence of functionally active thrombin on fibrin prepared from in vitro clots and in vivo thrombi as well as in association with soluble plasmic derivatives of these substrates. This activity may constitute a prothrombotic influence and may contribute to the elevated FPA-levels seen in patients with thrombotic disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6223106

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  20 in total

1.  Enhancing Thrombolysis with Adjunctive Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

2.  Role of clot-associated (-derived) thrombin in cell proliferation induced by fibrin clots in vitro.

Authors:  E Gandossi; C Lunven; C N Berry
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

Review 3.  [Emergencies in phlebology].

Authors:  F Pannier; E Rabe
Journal:  Hautarzt       Date:  2004-06       Impact factor: 0.751

4.  Crystal structure of the complex between thrombin and the central "E" region of fibrin.

Authors:  Igor Pechik; Joel Madrazo; Michael W Mosesson; Irene Hernandez; Gary L Gilliland; Leonid Medved
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-20       Impact factor: 11.205

Review 5.  New anticoagulant strategies. Current status and future potential.

Authors:  J Weitz
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

6.  Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B.

Authors:  R M Senior; W F Skogen; G L Griffin; G D Wilner
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

7.  Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.

Authors:  D J Fitzgerald; G A Fitzgerald
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

8.  Importance of factor Xa in determining the procoagulant activity of whole-blood clots.

Authors:  P R Eisenberg; J E Siegel; D R Abendschein; J P Miletich
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

9.  Clot retraction affects the extent of ultrasound-enhanced thrombolysis in an ex vivo porcine thrombosis model.

Authors:  Jonathan T Sutton; Nikolas M Ivancevich; Stephen R Perrin; Deborah C Vela; Christy K Holland
Journal:  Ultrasound Med Biol       Date:  2013-03-01       Impact factor: 2.998

10.  Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.

Authors:  P J Hogg; C M Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.